Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.

Rheumatoid arthritis (RA) is a chronically systemic autoimmune disorder, which is related with various cellular signal pathways. Both BTK (Bruton's Tyrosine Kinase) and JAK3 (Janus Kinase 3) play important roles in the pathogenesis of rheumatoid arthritis. Herein, we reported the discovery of dual BTK/JAK3 inhibitors through bioisosterism and computer-aided drug design based on the structure of BTK inhibitor ibrutinib. We reported the discovery of dual BTK/JAK3 inhibitors which are based on the structure of BTK inhibitor ibrutinib via the method of bioisosterism and computer-aided drug design) Most of the target compounds exhibited moderate to strong inhibitory activities against BTK and JAK3. Among them, compound XL-12 stood out as the most promising candidate targeting BTK and JAK3 with potent inhibitory activities (IC50 = 2.0 nM and IC50 = 14.0 nM respectively). In the in vivo studies, compound XL-12 (40 mg/kg) exhibited more potent antiarthritic activity than ibrutinib (10 mg/kg) in adjuvant arthritis (AA) rat model. Furthermore, compound XL-12 (LD50 > 1600 mg/kg) exerted improved safety compared with ibrutinib (LD50 = 750 mg/kg). These results indicated that compound XL-12, the dual BTK/JAK3 inhibitor, might be a potent drug candidate for the treatment of RA.

Synthesis, characterization, antioxidant activities, and DNA-binding studies of (E)-N'-[1-(pyridin-2-yl)ethylidene]isonicotinohydrazide and its Pr(III) and Nd(III) complexes.

A new ligand, (E)-N'-[1-(pyridin-2-yl)ethylidene]isonicotinohydrazide (HL), was prepared by condensation of 2-acetylpyridine and isonicotinohydrazide in ethanol. Its two lanthanide(III) complexes, [Nd(III)(L)(2)(NO(3))(CH(3)OH)(2)]·CH(3)CH(2)OH (1), and [Pr(III)(L)(2)(NO(3))(CH(3)OH)(2)]·CH(3)CH(2)OH (2), have been synthesized and characterized on the basis of element analyses, molar conductivities and IR spectra. The structure of complex 2 has been confirmed by X-ray diffraction. In addition, the DNA-binding properties of the two complexes have been investigated by electronic absorption spectroscopy, fluorescence spectroscopy, circular dichroic (CD) spectroscopy and viscosity measurements. The experimental results suggest that the two complexes bind to DNA via a groove binding mode, and the binding affinity of complex 2 is higher than that of complex 1. Furthermore, the antioxidant activities (superoxide and hydroxyl radical) of the ligand and its metal complexes were determined by spectrophotometry methods in vitro. These complexes were found to possess potent antioxidant activity and be superior to standard antioxidant like mannitol.